Eli Lilly and Company announced changes to its executive leadership team. Mike Mason, executive vice president and president of Lilly Diabetes and Obesity, will retire from Lilly at the end of 2023 after 34 years with the company. Over the last two decades, Mason has served in the leadership of Lilly’s Neuroscience and Diabetes businesses…
Eli Lilly and Company and POINT Biopharma Global, Inc. announced a definitive agreement for Lilly to acquire POINT, a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. Radioligand therapy can enable the precise targeting of cancer by linking a radioisotope to a targeting molecule that delivers radiation directly…
Global pharma major, Lupin Limited (Lupin) announced that it has signed a royalty-free, limited, non-exclusive voluntary licensing agreement with Eli Lilly and Company (Lilly) for manufacturing and selling of Lilly’s drug Baricitinib in India. Lilly has received permission from Central Drugs Standard Control Organization (CDSCO), Ministry of Health, for restricted emergency use of Baricitinib in…
Sun Pharmaceutical Industries Ltd. announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company (Lilly) for expanding access to Lilly’s drug, baricitinib in India. Sun Pharma will manufacture and distribute the drug in India, the release said. Baricitinib is used in combination with remdesivir for the treatment of…
Cipla Limited announced it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company, USA for the manufacture and commercialization of the drug baricitinib for Covid-19 indication. Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India for use in combination with…
Eli Lilly and Prevail Therapeutics Inc. have announced a definitive agreement for Lilly to acquire Prevail for $1.040 billion. Prevail is a biotechnology company developing potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases. The acquisition will establish a new modality for drug discovery and development at Lilly, extending Lilly’s research efforts through the…
Lilly, a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world has announced a definitive agreement to acquire Disarm Therapeutics, a privately-held biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration. Disarm has discovered novel, potent SARM1 inhibitors and…
Northwestern Mutual, a leading financial security company, announced that it has appointed Aarti S. Shah to the company’s board. Her appointment takes effect March 1, 2020. Shah is the senior vice president and chief information and digital officer for Eli Lilly and Company, a global healthcare leader. She is an accomplished executive with extensive experience…